Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: A retrospective case-control study

Clinical Rheumatology

Volumn 32, Issue 5, 2013, Pages 679-683

  Cozzi, F ^a   Pigatto, E ^a   Rizzo, M ^a   Favaro, M ^a   Zanatta, E ^a   Cardarelli, S ^a   Riato, L ^a   Punzi, L ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bosentan; Case control study; Digital ulcers; Systemic sclerosis

Indexed keywords

BOSENTAN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FINGER ULCER; HUMAN; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

AGED; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; FINGERS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RECEPTORS, ENDOTHELIN; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 84878719341     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2172-z     Document Type: Article

References (25)

1. Wigley FM (2009) Vascular disease in scleroderma. Clin Rev Allerg Immunol 36:150-175
2. Chung L, Fiorentino D (2006) Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 5:125-128
3. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G, Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc) (2002) Systemic sclerosis: demographic, clinical and serologic features and survival in 1,012 Italian patients. Med (Baltimora) 81:139-153
4. Steen V, Denton CP, Pope JE, Matucci-Cerinic M (2009) Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology 48(Suppl 3):19-24
5. Tiso F, Favaro M, Ciprian L, Cardarelli S, Rizzo M, Tonello M, Ruffatti A, Cozzi F (2007) Digital ulcers in a cohort of 333 scleroderma patients. Reumatismo 59:21-220
6. Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V, Hatron PY (2007) Natural history of ischemic digital ulcers in systemic sclerosis: single-centre retrospective longitudinal study. J Rheumatol 34:2423-2430
7. Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, Zultak M, Matucci-Cerinic M, DUO Registry investigators (2012) Demographic, clinical and antibody characteristic of patients with digital ulcers in systemic sclerosis: data from the DUO registry. Ann Rheum Dis 71:718-721
8. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, Co-Authors EUSTAR (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620-628
9. Korn JH, Mayes M, Matucci-Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C (2004) Digital ulcers in systemic sclerosis. Prevention by treatment with Bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985-3993
10. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32-38
11. Launay D, Diot E, Pasquier E, Mouthon L, Boullanger N, Fain O, Jego P, Carpentier P, Hatron PY, Hachulla E (2006) Bosentan for treatment of active digital ulcers in patients with systemic sclerosis. Presse Med 35:587-592
12. Riccardi MT, Chialà A, Iannone F, Grattagliano V, Covelli M, Lapadula G (2007) Treatment of digital ulcers in systematic sclerosis with endothelin-1 receptor antagonist (bosentan). Reumatismo 59:135-139
13. Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S (2006) Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 36(Suppl 3):49-53
14. Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S, Conforti ML, Kaloudi O, Nacci F, Sacu O, Candelieri A, Pignone A, Rasero L, Conforti D, Matucci-Cerinic M (2010) Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatol 49:1374-1382
15. Bérezné A et al (2011) Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res 63:277-285
16. Mouthon L, Mestre-Stanislas C, Bérezné A, Rannou F, Guilpain P, Revel M, Pagnoux C, Guillevin L, Fermanian J, Poiraudeau S (2010) Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 69:214-217
17. Cozzi F, Tiso F, Lopatriello S, Ciprian L, Sfriso P, Berto P et al (2010) The social costs of digital ulcer management in scleroderma patients: an observational Italian pilot study. Joint Bone Spine 77:83-84
18. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, Kashiwagi H (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19:1566-1571
19. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V, Valesini G, Santucci A (1995) Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 99:255-260
20. Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48:1190-1199
21. Tzifetaki N, Botzoris V, Alamanos Y, Argyriou E, Zioga A, Drosos AA (2009) Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year follow-up study. J Rheumatol 36:550-1552
22. García de la Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M, Carmona L, Gámir Gámir ML, Beltrán Gutiérrez J, Díaz-Miguel C, Orte Martínez J, Zea Mendoza AC (2008) Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatol 47:464-466
23. Roman Ivorra JA, Simeon CP, Alegre Sancho JJ, Equrbide MV, Castillo MJ, Lloria X, Fonollosa V (2011) Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study. J Rheumatol 38:1631-1635
24. Funauchi M, Kishimoto K, Shimazu H, Nagare Y, Hino S, Yano T, Kinoshita K (2009) Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int 29:769-775
25. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66:754-763